rivoceranib,camrelizumab,sorafenib
bayer,jiangsu hengrui pharmaceuticals,elevar therapeutics
['sorafenib', 'hcc', 'camrelizumab', 'rivoceranib']
presented today at #esmo22, new 1l treatment option in unresectable hepatocellular carcinoma (uhcc)! a phase iii trial found camrelizumab + rivoceranib (c+r) significantly prolonged pfs and os and improved orr compared to sorafenib (s) alone. share your thoughts in the comments! 